The Future Awakens
Experts in the cell and gene therapy space are excited about things to come. And why should they not be? After all, these are the pioneers of a burgeoning field of medicine.
The annual cell and gene supplement returns with a league of extraordinary professionals sharing what they know and how they expect the industry to develop, whilst exercising an optimistic caution for the future of this still young area of expertise. There remain challenges ahead, including in the logistics department of a highly regulated supply chain, as discussed by Sumukhi Sreevatsan, general manager, IMAPAC; and Caszyme CEO Monika Paul highlights the vital role of accurate information. Other illustrious names joining the discussion include Eric Rhodes, ERS Genomics; Vered Caplan, Orgenesis; and Chelsea Pratt, Bio-Rad Laboratories. Also in the supplement:
- Investor enthusiasm versus economic crisis
- Juggling industry with academia
- Sitting Down With … Tirtha Chakraborty
Get ready for the future
Sponsors
In recent years, new technologies have emerged to improve human living conditions. Two popular examples are cell therapy, where cells are enriched or modified before being introduced to the patient, and gene therapy, where genes are introduced, replaced, or altered within the body. Consolidated as cell and gene therapies, both are projected to revolutionize the treatment of genetic or acquired diseases, such as cancer.
In order to further advance the development of these innovative treatment options, Eppendorf has emerged as an expert partner for bioprocess by utilizing its strong synergies in cell culture, bioreactor technology, and polymer manufacturing.
Our bioprocess solutions support the upstream bioprocessing cycle to facilitate process development from small to pilot‐scale. Powerful hardware and software tools for process monitoring, control, and analytics help to build process understanding and facilitate standardized process control.
Eppendorf and its more than 5000 employees use their broad knowledge and experience to support laboratories and research institutions around the world in our mission to improve human living conditions.
With our equipment, training programs, and application services, we support scientists in resolving cultivation bottlenecks during development and help to bring life-saving treatments to the world.
Gene therapies hold the promise to change lives. Even as the path to patients accelerates, manufacturing and regulatory complexity remains a challenge. With limited process templates, evolving regulatory guidance, and urgent patient needs, finding a partner with experience is critical to your success.
From solving your unique upstream and downstream challenges, to meeting urgent manufacturing timelines, and navigating uncertain regulatory guidelines, a knowledgeable partner can help move your gene therapy from hype to hope.
At MilliporeSigma, we’re giving shape to gene therapy development every day. We bring 30+ years of expertise, and a global organization to integrate leading manufacturing technologies with process development, scale-up, safety testing, and the regulatory experience to meet your therapy’s needs.
We have more experience in this area than almost anyone else in the industry. We were the first gene therapy CDMO to produce commercial product following successful regulatory inspection. Our products and services include optimized manufacturing platforms, media and reagents; manufacturing, biosafety and characterization testing, as well as process development services.
Draw on our experience to bring your gene therapies to life.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,700 employees in 23 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
Thermo Fisher Scientific’s CDMO services group has the technical expertise, capacity, and global supply network that are critical to transitioning your advanced therapy product seamlessly from clinical to commercial phases with confidence. We bring over two decades of cGMP advanced therapy manufacturing experience and have manufactured more than 700 viral vector cGMP clinical and commercial lots, with 2 commercially approved products and several others pending. With an expansive support network and 15+ facilities strategically located across the globe in support of our advanced therapy customers, we are prepared to tackle projects of any scope and meet your unique needs and timelines.
Our industry-leading, end-to-end capabilities for advanced therapies include translational services, the development and manufacturing of plasmid DNA, viral vectors, cell therapy products, and mRNA, as well as cold and ultra-cold supply chain management and logistics. In a complex and constantly evolving market, we are a trusted partner that provides you with the personalized support and adaptability to help navigate industry challenges together.
Learn more at www.patheon.com/advancedtherapies.
